Literature DB >> 1544830

Bioreductive mechanisms.

P Workman1.   

Abstract

The design, development, and application of bioreductive antitumor agents in a rational way requires a detailed understanding of the mechanisms involved in their action. In addition to measuring and manipulating tumor hypoxia, we need to elucidate the particulars of the activation versus bioprotection pathways and the nature and properties of the participating enzymes. These areas are reviewed with particular reference to the development of novel quinone, nitro and N-oxide bioreductives.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544830     DOI: 10.1016/0360-3016(92)90493-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Oncogenic potential of bifunctional bioreductive drugs.

Authors:  T K Hei; S X Liu; E J Hall
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 3.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 4.  Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia.

Authors:  Simon P Robinson; John R Griffiths
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-06-29       Impact factor: 6.237

5.  DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours.

Authors:  A Marín; A López de Cerain; E Hamilton; A D Lewis; J M Martinez-Peñuela; M A Idoate; J Bello
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.

Authors:  M Maliepaard; A Wolfs; S E Groot; N J de Mol; L H Janssen
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

7.  A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.

Authors:  C P Lee; G S Payne; A Oregioni; R Ruddle; S Tan; F I Raynaud; D Eaton; M J Campbell; K Cross; G Halbert; M Tracy; J McNamara; B Seddon; M O Leach; P Workman; I Judson
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

Review 8.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

9.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Authors:  A V Patterson; H M Barham; E C Chinje; G E Adams; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

10.  DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.

Authors:  J A Plumb; M Gerritsen; P Workman
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.